TERBIUM-161 Isotopes Non-Carrier added (NCA) lanthanide Terbium-161(Tb-161) is is produced by neutron activation of Gadolinium-160 and offers a unique decay profile, setting new standards for targeted radioligand therapy (RLT) Home / Product / Isotopes / TERBIUM-161 Connect with Our Experts Get Tailored Supply Solutions Contact Us Next-Generation Radionuclide for Precision Oncology Non-Carrier added (NCA) lanthanide Terbium-161(Tb-161) is is produced by neutron activation of Gadolinium-160 and offers a unique decay profile, setting new standards for targeted radioligand therapy (RLT). Radioligand Therapy Using PSMA and SST analogues, Terbium-161 has shown excellent bioequivalence presenting a biodistribution comparable to the currently used radiolanthanides. Additionally, the 16-fold increase in Auger and conversion electrons is expected to improve the cellular absorbed dose up to 3-fold compared to currently used radiolanthanides, while allowing for treatment of both primary and undetectable (micro) metastasis, improving the overall disease control. Imaging Optimized Allowing optimization of the SPECT reconstruction parameters, Terbium-161 may provide for higher spatial resolution SPECT imaging, leading to the detection of smaller lesions that provides input for a further optimized treatment plan. Radiation Safety Terbium-161 provides for an immediate decrease in dose rate allowing for a significant improvement in general radiation safety. This optimization of radiation safety may extend current treatment room capacity for Radioligand Therapy. The non-carrier added (NCA) product allows optimal control of radioactive waste flow with reduced decay time in local storage. PRODUCT INFORMATION Potential indications Prostate, Breast, Neuroendocrine and Solid Cancers Formulation Tb-161 in aqueous 0.05M HCl Decays to stable Dy-161 Chemical Purity >99% ( ICP-MS) Radiochemical purity >99% ( TLC ) Half-life 6.967 ( 11 ) days ( 2022 update ) Emission B:154keV(平均)、y49 keV(17%)、75 keV ( 10%) 𝛃- 154KeV (average) 𝛄 49keV (17%) 75keV (10%) Therapeutic Advantages High LET Conversion & Auger electrons Factor 3 higher cellular absorbed dose High LET Conversion & Auger electrons Available Global supply since Q1 2023 Download Specifications Our mission is to accelerate the clinical accessibility of novel radionuclides, such as Terbium-161 (Tb-161), providing oncologists and researchers with powerful tools to drive new advancements in cancer treatment. In partnership with TerThera, we are committed to supporting the continued development of next-generation Radioligand Theranostics (RLT). Contact us First Name Last name Email Phone Message 送出
